Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

@inproceedings{Fischereder2016EmpagliflozinCO,
  title={Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.},
  author={Michael Fischereder and Ulf Sch{\"o}nermarck},
  year={2016}
}
Early Glycaemic Control in Metformin Users Receiving Their First Add-On Therapy: A Population-Based Study of 4,734 People with Type 2 Diabetes Thomsen RW, Baggesen LM, Sogaard M, et al Diabetologia. 2015;58:2247-2253 This observational cohort study used electronic databases in Northern Denmark from 2000 to 2012 to assess glycemic control of people who initiated metformin monotherapy and then added another glucose-lowering agent within 3 years. Specifically, the investigators examined attainment… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 1,677 CITATIONS, ESTIMATED 52% COVERAGE

Cardiovascular outcome trials of glucose-lowering medications: an update

  • Diabetologia
  • 2018
VIEW 19 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 172 Highly Influenced Citations

  • Averaged 440 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES